propofol hemisuccinate (EP102)
/ Epalex
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 18, 2025
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety-Tolerability of a Single Oral Dose of EP102 200mg or 400mg Self-Administered at Home By Adult Participants Experiencing Moderate to Severe Migraine Headache
(ANZCTR)
- P2 | N=480 | Not yet recruiting | Sponsor: Epalex Australia
New P2 trial • CNS Disorders • Migraine • Pain
1 to 1
Of
1
Go to page
1